HAYWARD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ...
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with ...
The last time I spoke about Immuneering Corporation (IMRX) it was in a Seeking Alpha article entitled "Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst." With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results